Ami Shah
Rheumatology · Baltimore, MDNPI 1962548651
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (58.4%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Argenx US, Inc. accounts for 76.3% of it on its own, with 3 other manufacturers making up the rest. 2025 is the largest year on record at $1,284, 6.8 times the $188 reported in 2019. That places this record below the midpoint for rheumatology clinicians in MD, where the typical reported total is $2,316.
Across 12 payments — averaging $140.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Argenx US, Inc.$1K
- Sanofi-aventis U.S. LLC$188
- Janssen Scientific Affairs, LLC$148
- AstraZeneca$61
Across 33 payments — averaging $10,471 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$159K
- Pfizer$137K
- Argenx US, Inc.$46K
- Kadmon Corporation LLC$3K
What the payments were for
- Consulting fees$18811%
- Travel & lodging$98258%
- Food & beverage$51230%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Argenx US, Inc. | 9 | $1,284 |
| Sanofi-aventis U.S. LLC | 1 | $188 |
| Janssen Scientific Affairs, LLC | 1 | $148 |
| AstraZeneca | 1 | $61 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYVGART HYTRULO$1,106
- SAR156597$188
- Tremfya$148
How this compares
$1,682 in reported general payments places this provider in the 40th percentile of 173 rheumatology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 19 | $269,217 |
| Actemra ActpenTocilizumab | 11 | $76,324 |
| Mycophenolate Mofetil | 83 | $32,649 |
| Hydroxychloroquine Sulfate | 44 | $1,975 |
| Pentoxifylline | 12 | $611 |
| MethotrexateMethotrexate Sodium | 14 | $475 |
| Famotidine | 14 | $351 |
| Amlodipine Besylate | 52 | $283 |
| Omeprazole | 13 | $99 |
| Mirtazapine | 12 | $84 |
| Tramadol Hcl | 11 | $0 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Baltimore
- Michelle PetriBaltimore$381K
- Marc HochbergBaltimore$124K
- Clifton BinghamBaltimore$117K
- Lisa ChristopherBaltimore$92K
- Philip SeoBaltimore$84K
- Laura HummersBaltimore$80K
- Rachel WallworkBaltimore$71K
- Thomas Grader BeckBaltimore$55K
- Andrea FavaBaltimore$38K
- Christopher MecoliBaltimore$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.